Background: In children with growth disorders, mean final height is associated to poor adherence to Growth Hormone therapy. The primary goal of this study is to identify patients who do not adhere to GH therapy and determine the influence of adherence in response to the treatment. The role of serum IGF-I and influence of socio-economic factors on the therapeutic adherence will also be evaluated.
Methods: 158 children under treatment with rhGH were included in the study. Age, gender, etiology, Tanner stage, duration of treatment, growth rate, IGF-I serum values, daily dose, and annual rhGH dose data were collected. Adherence to therapy was defined as moderate-to-poor when the patient had taken less than 92% of the prescribed medication. A subgroup of 106 patients completed a questionnaire to assess social and environmental effects.
Results: Moderate-to-poor adherence to rhGH treatment was determined in 33.5% of study patients. A decrease in adherence was associated to treatment duration (p=0.001). A significant correlation was determined between adherence and height velocity (p=0.002) and IGF-I (p<0.0001) levels. Adherence rates were associated to the mother's educational level (p=0.007).
Conclusion: Poor adherence to GH therapy was observed in one-third of study patients, resulting in suboptimal growth. IGF-I levels can be helpful to identify patients with poor adherence to GH medication. Physicians should pay special attention to certain characteristics of the patient and their environment, and encourage desirable therapeutic compliance.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ghir.2015.12.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Severe Lipoatrophy in a Growth Hormone Deficient Toddler Girl Treated with a Non-Pegylated Long-Acting Growth Hormone.
Children (Basel)
January 2025
Pediatric Research Center, New Children's Hospital, University of Helsinki, Helsinki University Hospital, 00290 Helsinki, Finland.
Background: Recombinant growth hormone (rhGH) has been used since 1985 to treat growth hormone (GH)-induced short stature, typically associated with transient adverse events. However, lipoatrophy, characterized by irreversible damage to subcutaneous fat, was first reported in 1999 and linked to antibody formation. In 2021, localized lipoatrophy was observed in 14.
View Article and Find Full Text PDFLong-acting growth hormones: innovations in treatment and guidance on patient selection in pediatric growth hormone deficiency.
Ann Pediatr Endocrinol Metab
January 2025
Department of Medicine, Surgery and Health Science, University of Trieste, Trieste, Italy.
Long-acting growth hormones (LAGHs) represent a significant advancement in the treatment of pediatric growth hormone deficiency (GHD), offering an alternative to daily recombinant human growth hormone (rhGH) therapy. Traditional rhGH treatments, while effective, require daily injections, often leading to poor adherence due to the frequency of dosing, injection pain, and difficulties with storage and travel. In contrast, LAGHs, such as somatrogon, somapacitan, and lonapegsomatropin, are designed for once-weekly administration, improving patient compliance and quality of life.
View Article and Find Full Text PDFA novel Y-shaped pegylated recombinant human growth hormone for children with growth hormone deficiency: a phase 3 study.
J Clin Endocrinol Metab
November 2024
Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Article Synopsis
- Pegpesen® is a new once-weekly treatment for growth hormone deficiency (GHD) in children, designed to offer an alternative to daily human growth hormone therapy.
- A phase 3 clinical trial involving 391 children showed that Pegpesen® had a growth velocity similar to daily rhGH, indicating it is non-inferior.
- The safety and adherence profiles for Pegpesen® were comparable to daily rhGH, suggesting it could be a beneficial option due to lower dosage requirements.
Recombinant GH Therapy: Expected Results, Modalities and Monitoring in Children.
Front Horm Res
November 2024
Endocrinology and Diabetes Unit, IRCCS "Bambino Gesù" Children's Hospital, Rome, Italy.
Article Synopsis
- - Growth hormone treatment has evolved from using pituitary-derived GH for specific cases of GH deficiency to recombinant human GH (rhGH), which is now approved for various disorders beyond just GH deficiency.
- - RhGH significantly helps improve short stature in GH-deficient patients and has positive effects on metabolic and bone health, with long-term safety studies showing encouraging results, particularly for those with isolated GHD.
- - New long-acting rhGH formulations are being developed to enhance adherence to treatment and lessen the burden on patients, while ongoing surveillance is needed for safety in higher doses or other clinical conditions.
Preferences for Injection Device Settings and the Association with Adherence to Growth Hormone Treatment in Patient with Growth Disorders.
Stud Health Technol Inform
August 2024
Global Medical Affairs Cardiometabolic & Endocrinology, Merck Healthcare KGaA, Darmstadt, Germany.
Adherence to recombinant human growth hormone (r-hGH; somatropin, [Saizen®], Merck Healthcare KGaA, Darmstadt, Germany) treatment is important to achieve positive growth and other outcomes in children with growth disorders. Automated injection devices can facilitate the delivery of r-hGH, injections of which are required daily for a number of years. The ability to adjust injection device settings may improve patient comfort and needle anxiety, influencing adoption and acceptance of such devices, thereby improving treatment adherence.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!